Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,050 recruiting studies in this area right now.
By phase
- Not applicable2,999
- Phase 21,056
- Phase 1792
- Phase 1/Phase 2437
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes130
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland199
- Alabama178
- Florida149
- Arizona148
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,050 total
- NCT07382817RecruitingPhase 1
A study of CAR T cells for patients with certain T or NK cell cancers
This trial tests whether a new treatment, called CAR T cells that target CD94, can help people with specific types of T or NK cell lymphoma or leukemia that have not responded to other treatments or have come back. The goal is to see if it is safe and works against the cancer.
Houston, TexasAges 18 years+ - NCT07380113RecruitingPhase 4
Comparing two drugs for sleep in dialysis patients with itch
This trial tests if anrikefon or nalfurafine improves sleep quality in people on hemodialysis who have chronic kidney disease-related itching. It aims to find a better treatment for both itch and sleep problems.
Guangzhou, GuangdongAges 18–75 - NCT06129214Recruiting
Partial tendon cleaning to reduce knee clicking after replacement
This trial studies a partial cleaning procedure on the quadriceps tendon during knee replacement to reduce clicking or rubbing sensation (crepitus). It is only for people getting a specific type of knee implant (posterior-stabilized) and whose kneecap is not replaced.
Seoul, GangnamGuAges 19 years+ - NCT06608797Recruiting
Computer-based cognitive training for multiple sclerosis patients
This study tests whether a computer-based cognitive training program is helpful and practical for people with multiple sclerosis who live in the community. It focuses on those who have some memory or learning difficulties.
East Hanover, New JerseyAges 19–65 - NCT06735053Recruiting
Virtual reality physiotherapy for multiple sclerosis patients
This trial tests whether virtual reality exercises can help people with advanced multiple sclerosis improve their movement and walking. You may qualify if you need two walking aids and your MS has been stable for the last six months.
Móstoles, MadridAges 18–70 - NCT06839898Recruiting
Study of two implantable astigmatism-correcting lenses
This study tests two types of implantable lenses that correct astigmatism (blurry vision from an irregularly shaped cornea). You keep your own natural lens, and the new lens is placed in front of it—no laser or lens removal needed. The goal is to see which lens works better and is safer.
Münster, North Rhine-WestphaliaAges 21 years+ - NCT06788652Recruiting
Study of Liso-cel for mantle cell lymphoma after market approval
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
Milwaukee, WisconsinAges 18 years+ - NCT06841042RecruitingPhase 1/Phase 2
Testing a new drug for active lupus
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
BeijingAges 18–75 - NCT04993885RecruitingPhase 2
Avatrombopag for adults with immune low platelets
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05199909RecruitingPhase 2
Testing zanubrutinib for antiphospholipid syndrome with low platelets
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05214391RecruitingPhase 2
Zanubrutinib for chronic immune low platelets after prior treatments
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06281327RecruitingPhase 2
Avatrombopag for children with ITP switching from eltrombopag
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
TianjinAges 6–18 - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT07371923RecruitingPhase 2
Zanubrutinib combination therapy for newly diagnosed high-risk DLBCL
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07377435RecruitingPhase 1
Vaccine after CAR-T therapy for multiple myeloma
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Boston, MassachusettsAges 18 years+ - NCT07372365RecruitingPhase 2
Orelabrutinib after initial therapy for new marginal zone lymphoma
This trial tests an oral medication called orelabrutinib as a follow-up treatment after initial therapy for marginal zone lymphoma that hasn't been treated yet. The goal is to see if it helps keep the lymphoma from coming back.
Suzhou, JiangsuAges 18 years+ - NCT07376772Recruiting
Wearable vibration therapy for arm and hand function in multiple sclerosis
This study tests if a wearable device that gently vibrates the arm can improve hand and arm function in people with multiple sclerosis. You would use the device at home while doing daily activities.
Gainesville, FloridaAges 18–100 - NCT07374874Recruiting
Heart and nervous system health after stem cell transplant
This study looks at how your autonomic nervous system (the part that controls heartbeat and digestion) affects the risk of graft-versus-host disease (a condition where donor cells attack your body) after a half-matched stem cell transplant. You may be able to join if you are older than 16 and receiving a half-matched transplant from a family donor.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT07372170Recruiting
Blood thinners for preventing another clot in low-risk APS
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
Madrid, MadridAges 18 years+ - NCT07374705Recruiting
Brain insulin resistance and health in diabetes
This study looks at how insulin resistance in the brain affects brain health. If you have type 1 or type 2 diabetes and are between 50 and 80 years old, you may be able to join to help researchers understand brain changes.
Glostrup MunicipalityAges 50–80 - NCT07377305Recruiting
Brain stimulation for nerve pain in NMOSD
This trial tests a new, non-invasive brain stimulation method (tTIS) to treat chronic nerve pain in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to see if this treatment is safe and can reduce pain without surgery or drugs.
Xi'an, ShaanxiAges 18–75 - NCT07376733Recruiting
Breathing exercises for heart and lung health in multiple myeloma
This study looks at whether simple, guided breathing exercises can improve heart and lung health in people with multiple myeloma. It may help you feel stronger and manage side effects during treatment.
MadridAges 18 years+ - NCT07378527RecruitingPhase 2/Phase 3
Study of ICP-332 for chronic hives not helped by antihistamines
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
Bengbu, AnhuiAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,050 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,115 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.